Ft Lauderdale, Florida 3/25/2010 7:45:00 AM
News / Business

PPD Inc (NASDAQ:PPDI) Appoints Frank Gallo as Executive Director of Risk Management

 

PPD, Inc. (NASDAQ:PPDI) has announced the appointment of Frank Gallo as the executive director of risk management.  Mr. Gallo’s role will be to strengthen the company’s expertise in risk evaluation and mitigation strategies (REMS).  He will lead the development, management and implementation REMS programs aligning with client program goals and product commercialization.

 

Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.

 

Gallo has over 13 years of pharmaceutical, commercial and risk management experience.  He has served as the vice president of Rienzi & Rioenzi where he was responsible for the development and design of REMS communications strategies and programs for the United States Food and Drug Administration (FDA) approval.  He has alos held risk management and commercial positions with Talecris Biotherapeutics and Mylan, Inc.

 

Pharmaceutical Product Development, Inc. is a global contract research organization providing drug discovery and development services. Its clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. Its development services include preclinical programs and Phase I through Phase IV clinical development services, as well as bioanalytical, cGMP, global central laboratory and vaccines and biologics laboratory services. The Company operates in two segments: Development and Discovery Sciences. In May 2009, the Company completed its disposition of its wholly owned subsidiary Piedmont Research Center, LLC. In December 2009, the Company completed its disposition of its wholly owned subsidiary PPD Biomarker Discovery Sciences, LLC. On April 2, 2009, the Company acquired Magen BioSciences, Inc. On April 21, 2009, the Company acquired AbC.R.O., Inc. On November 6, 2009, the Company acquired Excel PharmaStudies, Inc.

 

Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.

 

Follow us on Twitter: http://www.Twitter.com/topbestps

 

About Us

 

Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.

 

Please click here to read the full disclaimer.